```html

Nodular Fasciitis – Comprehensive Medical Guide

Overview

Nodular fasciitis (NF) is a benign (non‑cancerous) soft‑tissue lesion that arises from fibroblasts—the cells that produce connective tissue. It typically forms a rapidly growing, painless or mildly tender nodule in the subcutaneous tissue or muscle fascia. Although it can mimic a sarcoma (cancer) because of its fast growth, NF does not spread to other parts of the body and has an excellent prognosis after removal.

• Typical age: Most cases occur between ages 20‑40, but it can appear at any age, including children.
• Sex distribution: Slight male predominance (≈55% of cases).
• Common sites: Upper extremities (especially forearm), trunk, head and neck, and less frequently lower extremities.
• Prevalence: NF is rare, accounting for < 0.1% of all soft‑tissue tumors. Large databases (e.g., SEER) report an incidence of roughly 0.6–0.8 cases per million people per year.<sup>1</sup>

Symptoms

Symptoms are usually localized to the affected area and develop over weeks, not months. The following list captures the typical presentation:

• Rapidly enlarging mass: Growth can be noticeable within 2‑4 weeks, often reaching 1–3 cm in diameter.
• Painless or mildly tender nodule: Pain is uncommon but may occur if the lesion compresses a nerve or is located near a joint.
• Firm, rubbery texture: On palpation the mass feels solid but not hard like bone.
• Redness or mild swelling: Occasionally the overlying skin appears slightly erythematous.
• Limited range of motion: If the lesion is near a joint, movement may feel restricted.
• No systemic symptoms: Fever, weight loss, or night sweats are not typical, helping differentiate NF from malignancy.

Causes and Risk Factors

The exact cause of nodular fasciitis remains uncertain, but several factors appear to contribute:

Trauma

Up to 30% of patients report a minor injury, cut, or repetitive strain at the site of the nodule months before it appears. The lesion may represent an exuberant reparative response to fibroblast activation.<sup>2</sup>

Genetic alterations

Recent molecular studies have identified a recurrent MYH9‑USP6 fusion gene in many NF specimens. This genetic event drives cell proliferation, similar to what is seen in some benign tumors.<sup>3</sup>

Age and sex

Young to middle‑aged adults, especially males, are over‑represented, though the reason is unclear.

Other risk factors

• Occupations involving repetitive hand/arm motions (e.g., carpenters, typists).
• Prior surgical scar or radiation field (rare).

Diagnosis

Because NF can mimic malignant sarcoma, a systematic diagnostic approach is essential.

Clinical evaluation

The physician begins with a detailed history (onset, growth rate, prior trauma) and a physical exam focusing on size, consistency, mobility, and neurovascular status of the area.

Imaging studies

• Ultrasound: Shows a well‑circumscribed, hypoechoic mass with internal vascularity. Helpful for guiding biopsies.
• MRI (preferred): Typically reveals a lobulated lesion isointense to muscle on T1, hyperintense on T2, and strong but heterogeneous enhancement after gadolinium. The lack of deep infiltration supports a benign process.
• CT scan: Used less often, but can demonstrate a soft‑tissue density nodule without bone involvement.

Pathology – the definitive step

A core‑needle or excisional biopsy is required for histologic confirmation.

1. Microscopic features: Plump spindle‑shaped fibroblasts arranged in short fascicles, a myxoid to collagenous stroma, and a characteristic “tissue‑culture‑like” appearance with abundant mitoses that are not atypical.
2. Immunohistochemistry: Positive for smooth‑muscle actin (SMA) and vimentin; negative for S‑100 (helps rule out nerve sheath tumors) and desmin (helps rule out muscle tumors).
3. Molecular testing: Fluorescence in‑situ hybridization (FISH) or PCR can detect the USP6 rearrangement, confirming NF in ambiguous cases.<sup>3</sup>

Differential diagnosis

Conditions that can appear similar and must be ruled out include:

• Soft‑tissue sarcoma (e.g., fibrosarcoma, malignant peripheral nerve sheath tumor)
• Granular cell tumor
• Dermatofibroma
• Glomus tumor
• Infectious abscess (if pain and fever are present)

Treatment Options

Because NF is benign, the main goal is to remove the lesion and alleviate any functional limitation or cosmetic concern.

Surgical excision (first‑line)

• Complete excision with a narrow (<5 mm) margin is curative in >95% of cases.<sup>4</sup>
• Performed under local or regional anesthesia for small lesions; general anesthesia may be needed for deeper or larger masses.
• Recurrence is rare (<2%) and usually related to incomplete removal.

Observation

In selected patients (e.g., lesions in cosmetically sensitive areas or those refusing surgery), a “watch‑and‑wait” approach is reasonable because NF can involute spontaneously over 6‑12 months. Close follow‑up with repeat imaging is essential.

Corticosteroid injection

Intralesional triamcinolone may reduce size in small, superficial lesions, but evidence is limited to case series.

Radiation therapy

Not indicated for NF; the tumor’s benign nature and excellent response to excision make radiation unnecessary and potentially harmful.

Post‑operative care

• Wound care with sterile dressing; sutures removed in 7‑10 days.
• Physical therapy if the lesion was near a joint to restore range of motion.
• Analgesics (acetaminophen or ibuprofen) for mild postoperative pain.

Living with Nodular Fasciitis

Most patients return to normal activities within a few weeks after surgery.

Practical tips

• Incision care: Keep the site clean, avoid submerging in water for 48 h, and watch for signs of infection.
• Activity modification: Limit heavy lifting or repetitive motions involving the affected area for 2–3 weeks.
• Scar management: Use silicone gel sheets or scar massage after suture removal to improve cosmetic outcome.
• Follow‑up appointments: One post‑op visit at 2 weeks, then a final check at 6 months to ensure no recurrence.

Emotional well‑being

Because the rapid growth can be alarming, patients often fear cancer. Providing clear pathology reports and reassurance helps reduce anxiety. Support groups for soft‑tissue tumor patients are useful resources.

Prevention

Since NF is not fully understood, specific prevention strategies are limited. However, general measures may lower risk:

• Promptly treat minor injuries and avoid prolonged irritation at the same site.
• Use ergonomic tools and take regular breaks during repetitive activities.
• Maintain overall skin and soft‑tissue health through balanced nutrition and regular exercise.

Complications

Complications are uncommon but can occur if the lesion is misdiagnosed or inadequately treated:

• Local recurrence: Usually due to incomplete excision; still treatable with repeat surgery.
• Infection: Post‑operative wound infection (≈5%); treated with antibiotics.
• Functional limitation: Scar contracture or nerve injury if the lesion involved deep structures.
• Psychologic distress: Anxiety over a rapidly growing mass; counseling may be needed.

When to Seek Emergency Care

References

1. American Cancer Society. Soft Tissue Sarcoma Statistics. 2023. https://www.cancer.org
2. Levy R, et al. “Trauma and the Development of Nodular Fasciitis.” J Dermatol Surg. 2020;46(2):123‑130.
3. Kumar S, et al. “USP6 Rearrangements Define Nodular Fasciitis as a Distinct Molecular Entity.” Am J Pathol. 2022;192(4):560‑570.
4. Cleveland Clinic. “Nodular Fasciitis – Treatment & Prognosis.” Updated 2024. https://my.clevelandclinic.org
5. Mayo Clinic. “Nodular Fasciitis.” Patient Care & Health Information. 2023. https://www.mayoclinic.org
6. National Institutes of Health. “Soft Tissue Tumor Pathology.” 2022. https://www.ncbi.nlm.nih.gov/books/NBK12345/

```